←
Lindonlight Collective427 posts
Lindonlight Collective avatar

Lindonlight Collective

@Lindonlight

To end pediatric brain cancer

◷ Joined April 2024▧ 4 Photos and videos
Dr. Foxpaws Fauxpas avatar
⟳ Lindonlight Collective retweeted
Dr. Foxpaws Fauxpas@foxpaws_onco·Mar 4

Continuing the #lung #cancer updates - 2025's practice changing updates in #lcsm DELLPHI304 Tarlatamab IMFORTE Lurbinectedin MARIPOSA VS FLAURA2 TROPION Dato DxD LUMINOSITY TelisoV WUKONG Sunvozertinib TRUST Taletrectinib BEAMION Zongertinib SOHO Sevabertinib

Post attachment
Samuel Hume avatar
⟳ Lindonlight Collective retweeted
Samuel Hume@DrSamuelBHume·Mar 1

I did a PhD in the biology of p53 so, given this week's news, I can't resist sharing some facts about it 1. Cancers are under intense selective pressure to inactivate p53, and there are >1,000 ways to do it 2. Even one molecule of mutant p53 within the functional tetramer can poison the whole complex — many of the mutations are dominant-negative 3. Some p53 mutations not only disrupt its anti-tumor function, but add new pro-tumor functions (these are the 'gain-of-function' mutations) We've known all of this for a long time, and it's amazing to see p53-reactivating therapies finally (slowly) having some success in the clinic

Post attachment

5 breakthroughs in medicine this week (I'm excited about this one) Read it here: breakingground.substack.com/…

Post attachment
Narendra Modi avatar
⟳ Lindonlight Collective retweeted
Narendra Modi@narendramodi·Feb 28

देश की बेटियां स्वस्थ और समृद्ध हों, इसके लिए हम कोई कोर-कसर नहीं छोड़ रहे हैं। इसी दिशा में आज सुबह करीब 11:30 बजे राजस्थान के अजमेर में एचपीवी टीकाकरण के देशव्यापी अभियान का शुभारंभ करूंगा। इस पहल का उद्देश्य सर्वाइकल कैंसर की रोकथाम है। इस दौरान कई परियोजनाओं के शिलान्यास और उद्घाटन के साथ ही अपने युवा साथियों को नियुक्ति पत्र देने का भी सुअवसर मिलेगा। pib.gov.in/PressReleasePage.…

Uğur Özkerim avatar
⟳ Lindonlight Collective retweeted
Uğur Özkerim@UOzkerim·Feb 28

📢📢Big day for HIF-2α inhibition — the Belzutifan era is expanding in RCC✅ 🧬LITESPARK-011 (2L mRCC) Belzutifan + lenvatinib vs cabozantinib PFS HR 0.70 24-mo PFS: 35.6% vs 19.1% Strong and clinically meaningful signal. 🧬LITESPARK-022 (adjuvant) Belzutifan + pembrolizumab vs pembro DFS HR 0.72 ~7% absolute gain at 2 yrs OS immature. From metastatic to adjuvant — HIF-2α inhibition is clearly entering prime time. @OncoAlert @OncoReporte @MedwatchKate @MedicalwatchHQ @weoncologists @Uromigos

Post attachmentPost attachmentPost attachmentPost attachment
Paolo Tarantino avatar
⟳ Lindonlight Collective retweeted
Paolo Tarantino@PTarantinoMD·Feb 28

Brief history of anti-p53 cancer treatments 👇

A brief history of p53-targeting cancer therapies 2003 — Gendicine, a p53 gene therapy, approved in China (but not elsewhere) 2012 — The first small molecule MDM2 inhibitor (RG7112, which works by preventing degradation of p53) enters trials, but did not progress to approval 2013 — Second-generation MDM2 inhibitor (Idasanutlin) reached phase 3, but failed and was dropped 2017 — A dual MDM2/MDMX inhibitor, ALRN-6924, enters trials; it has not since been approved 2020–2021 — A mutant p53 reactivator, Eprenetapopt, fails in phase 3 2023 — An MDM2 inhibitor, Milademetan, fails in phase 3 2024 — Promising phase 1 data for an MDM2 degrader 2026 — Rezatapopt phase 1 data: very promising early data, specific for the p53 Y220C mutation (present in 1% of all solid tumours)

Samuel Hume avatar
⟳ Lindonlight Collective retweeted
Samuel Hume@DrSamuelBHume·Feb 28

A brief history of p53-targeting cancer therapies 2003 — Gendicine, a p53 gene therapy, approved in China (but not elsewhere) 2012 — The first small molecule MDM2 inhibitor (RG7112, which works by preventing degradation of p53) enters trials, but did not progress to approval 2013 — Second-generation MDM2 inhibitor (Idasanutlin) reached phase 3, but failed and was dropped 2017 — A dual MDM2/MDMX inhibitor, ALRN-6924, enters trials; it has not since been approved 2020–2021 — A mutant p53 reactivator, Eprenetapopt, fails in phase 3 2023 — An MDM2 inhibitor, Milademetan, fails in phase 3 2024 — Promising phase 1 data for an MDM2 degrader 2026 — Rezatapopt phase 1 data: very promising early data, specific for the p53 Y220C mutation (present in 1% of all solid tumours)

NEJM@NEJMFeb 26

Original Article: Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors (PYNNACLE study) https://nej.md/3OIQC5P Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors https://nej.md/3N0pQW8 #Oncology #Genetics

Post attachment
Markus Tschurtschenthaler avatar
⟳ Lindonlight Collective retweeted
Markus Tschurtschenthaler@MarTschu·Feb 25

Our work is now published in @Nature. We introduce the Mouse Cancer Cell Line Atlas (MCCA) and reveal deterministic, tissue-specific rules of KRAS-driven cancer evolution. Huge thanks to the entire team & collaborators. nature.com/articles/s41586-0…

Gene Smith avatar
⟳ Lindonlight Collective retweeted
Gene Smith@GeneSmi96946389·Feb 27

Having two copies of APOE e2 is seriously like a genetic superpower. These people almost never get Alzheimer's, no matter how old they get.

Post attachment
Stephen V Liu, MD avatar
⟳ Lindonlight Collective retweeted
Stephen V Liu, MD@StephenVLiu·Feb 26

Real world intracranial efficacy of trastuzumab deruxtecan (T-DXd, HER2 ADC) in HER2 mutant NSCLC @JTOonline. Systemic RR 54.8%, PFS 7.2m, OS 18.3m across lines. As 1L, RR 72.2%, OS 22.1m. Intracranial RR 74.1% in 27 pts. ILD seen in 14% (4 fatal). jto.org/article/S1556-0864(2…

Paolo Tarantino avatar
⟳ Lindonlight Collective retweeted
Paolo Tarantino@PTarantinoMD·Feb 25

When a phase 1 trial is published in @NEJM, you can bet it will be impactful. Here, the p53 reactivator rezatapopt showed an ORR 20% among 77 pts with TP53 mutant (Y220C) advanced tumors. Are we getting closer to drug the most undruggable of all mutations? nejm.org/doi/full/10.1056/NE…

Post attachment
Path of Men avatar
⟳ Lindonlight Collective retweeted
Path of Men@PathOfMen_·Feb 22

Fast walkers have higher IQ & larger brains than slow walkers.

Post attachment
Paolo Tarantino avatar
⟳ Lindonlight Collective retweeted
Paolo Tarantino@PTarantinoMD·Feb 22

Will ADCs replace chemotherapy? 🎯

This Tuesday 2/24, I am joined by @PTarantinoMD of @DanaFarberNews @DFCI_BreastOnc who discusses "All things ADCs in Cancer." Wide range conversation that may generate more quetsions. Check out this clip, and mark your calendar this Tuesday morning for the full podcast.

1:20
Paolo Tarantino avatar
⟳ Lindonlight Collective retweeted
Paolo Tarantino@PTarantinoMD·Feb 20

What are the key issues that have emerged on the @NatureMedicine time-of-day IO paper? 1. The clinical trial protocol uploaded to Nature was v1 dated Jan 2, 2022; however, the protocol includes references published in 2024. This calls into question when the protocol was written and if/when it was amended. 2. The clinicaltrials.gov record is concerning and calls into question whether the study was actually randomized. a. In the first record 9/2022, although the study was noted as randomized, the inclusion/exclusion criteria read as though it was a retrospective study, e.g., “First-line patients received immunological monotherapy or immunological combined chemotherapy” as an inclusion criteria and  “Lack of clinical diagnosis and treatment information or loss of follow-up” as an exclusion criteria. b. In the first record, the primary endpoint, sample size, treatment and ECOG criteria do not match what was in the protocol dated Jan 2, 2022.  c. On 3/19/2024, the study was changed from randomized/interventional to an observational case-control study d. It was not until 3/30/2024 (2 months before end of randomization) that the study was changed to the design described in the manuscript. 3. The OS K-M curve presented at ASCO had errors – i.e., the censor marks do not match the at-risk table. This raises concerns about the integrity of statistical analyses. 4. The shape of the PFS does not match expectations. With a 6-week scan schedule, one would expect a stair-step drop every 6 weeks when patients have their scheduled imaging. Their PFS curve does not – it is smooth. Of note, in an observational study, a PFS curve generally does not have a staircase look because scans are not performed on a regular set schedule. 5. The 95% CI for the lower bound of the median OS in the manuscript is NE. This is not possible as the median was estimated. There are inconsistencies in the p-values in Table 1 (Baseline Characteristics) Credit to Daniel Brickman, Amanda Nottke and David Swank for creating this list — and to @houndcl for first identifying several of these issues.

Impressive job of post-publication Twitter peer review on this paper! With the effect size appearing inexplicably massive, plus the many inconsistencies in study conduct and reporting, it’s safe to assume the “time-of-day IO” question still fully open. nature.com/articles/s41591-0…

Post attachment
Anil Makam avatar
⟳ Lindonlight Collective retweeted
Anil Makam@AnilMakam·Feb 17

7/ 🚩#4 Infusion times are odd They cluster 9–12:30, then 3–6:30 With a 3-hour gap in between That’s not random timing around a 3pm cutoff That looks like two clinic sessions